Merck

Merck, as the oldest innovative pharmaceutical company in the world with strong commitment to innovation, and deep roots in Europe, welcomes the Commissions efforts to improve pharmaceutical legislation. The proposed regulatory changes, including measures to reduce assessment timelines, modernize and future-proof the EU regulatory network and its frameworks, e.g.

Merck, as the oldest innovative pharmaceutical company in the world with strong commitment to innovation, and deep roots in Europe, welcomes the Commissions efforts to improve pharmaceutical legislation. The proposed regulatory changes, including measures to reduce assessment timelines, modernize and future-proof the EU regulatory network and its frameworks, e.g.

The future EU frameworks for regulatory approval, access and incentives to innovation must be articulated around strong industrial policies, attractiveness and predictability, as key enablers to innovation and speeding up access to patients. The legislative review should support European developers and manufacturers in leading science progress and remaining competitive globally.

Merck welcomes the Commissions intention to make sustainability reporting simpler and more cost-effective for companies. However, there are still several significant new or changed requirements which add administrative burden and reduce comparability to previous Sustainability Statements.

Merck KGaA contribution to the Public Consultation on the European Commission’s proposed regulation of Artificial Intelligence (“AI Act”) First of all, we would like to thank the EU Commission for the opportunity to participate and discuss this important act and commend the effort to draft regulation on such a complex and multi-faceted topic. AI has a huge potential to solve today and future challenges.

Opening of the attached position paper · the full paper is on the Commission’s record (source link above)

The Biotech sector is facing several challenges that threaten and limit its competitiveness in the EU, among them: regulatory barriers, R&D investment gap, global competition, supply chain vulnerabilities. EU needs to operate decisive actions to tackle those challenges and enable its biotech industry and the ones behind them, to grow and create value.

Merck Life Science thanks the Commission for the opportunity to comment. We believe the proposed revision of CLP may constitute something of a missed opportunity to improve on labelling and communication and currently works counter to some of the stated aims of the revision.

Merck is deeply convinced that from a scientific point of view there is no comprehensible reasoning for the proposed classification as a CMR substance, hence Merck’s position is “no classification of titanium dioxide”.

First, we would like to thank the European Commission (EC) for the opportunity to participate and discuss this proposal. Data sharing is a critical element of the digital economy, which must contribute to a diverse and lively data ecosystem. It is necessary to navigate complex and ever-changing technologies. Efforts to incentivize data sharing are essential to fostering competitiveness and protecting end-user data.

As addressed within the European Green Deal we can make the EU´s economy more sustainable by turning climate and environmental challenges into opportunities. It is recognized that, to reach this target, actions by all sectors of our economy are required to innovate. Innovation and progress are coming with education, research, and autonomy.

Merck fully endorses the EU Safe Hearts Plan ambitions and welcomes CV Health Checks as a key EU initiative to advance population-level prevention and early disease detection. We stand ready to support its implementation from 2026 onwards, promoting harmonized, equitable monitoring of major cardiovascular risks to identify at-risk individuals and enable Member States to build consistent, evidence-based national…

Merck Life Science response to EU public consultation on Digital Product Passports rules for service providers public consultation: Merck Life Science would like to provide feedback on several key requirements that are essential for the successful implementation of Digital Product Passports (DPP). We supply scientists with the tools to carry out their work.

Merck KGaA supports a truly harmonised EU market with clear, predictable rules that protect human health and the environment while enabling access to effective biocidal products. In our view, the current functioning of the BPR does not meet these needs.

Merck welcomes the opportunity to comment on the proposals by the Commission to streamline regulatory processes and to improve cooperation between the agencies responsible for chemical management in the EU. Merck develops, manufactures, and markets high-quality medicines, innovative products for the biotech and pharmaceutical industries and for academic research as well as specialty chemicals for high-tech…

Merck, a leading science and technology company with headquarters in Germany, is strongly committed to developing innovative medicines in areas of unmet needs, improving patients clinical outcomes and quality of life. We share the European Commission’s (EC) goal to continue supporting medical innovation in areas of unmet needs and the European pharmaceutical industry as global leader in health innovation.

Merck welcomes the opportunity to comment on the proposals by the Commission to streamline regulatory processes and to improve cooperation between the agencies responsible for chemical management in the EU. Merck develops, manufactures, and markets high-quality medicines, innovative products for the biotech and pharmaceutical industries and for academic research as well as specialty chemicals for high-tech…

Merck welcomes the opportunity to comment on the draft Commission Implementing Regulation laying down the technical requirements of HealthData@EU. Merck would like to highlight areas where further clarifications or revisions would significantly enhance the implementation. Our comments are listed in the attached document.

Regarding Annex II of the draft amending regulation (Ares (2026) 7318336) (which refers to Annex V of EU Regulation 649/2012), we encourage you to provide us with support in implementing the regulations by listing CAS numbers in full, rather than concluding them with the phrase and others.